vs
Side-by-side financial comparison of Solowin Holdings, Ltd. (AXG) and Pasithea Therapeutics Corp. (KTTA). Click either name above to swap in a different company.
Solowin Holdings, Ltd. is the larger business by last-quarter revenue ($410.0K vs $240.7K, roughly 1.7× Pasithea Therapeutics Corp.). Solowin Holdings, Ltd. produced more free cash flow last quarter ($-1.6M vs $-4.5M).
Pasithea Therapeutics Corp. is a clinical-stage biopharmaceutical firm dedicated to developing novel treatments for psychiatric and neurological conditions including treatment-resistant mood disorders. It primarily operates in North American and European markets, targeting patient segments that lack effective existing treatment options.
AXG vs KTTA — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2022
| Metric | | |
|---|---|---|
| Revenue | $410.0K | $240.7K |
| Net Profit | — | $-5.1M |
| Gross Margin | — | — |
| Operating Margin | -34.1% | -1679.5% |
| Net Margin | — | -2126.1% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-1.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 24 | $410.0K | — | ||
| Q4 22 | — | $240.7K | ||
| Q3 22 | — | $218.6K | ||
| Q2 22 | — | $13.6K | ||
| Q1 22 | — | $13.7K |
| Q3 24 | — | — | ||
| Q4 22 | — | $-5.1M | ||
| Q3 22 | — | $-4.6M | ||
| Q2 22 | — | $-2.7M | ||
| Q1 22 | — | $-1.6M |
| Q3 24 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | 60.4% | ||
| Q2 22 | — | — | ||
| Q1 22 | — | 5.3% |
| Q3 24 | -34.1% | — | ||
| Q4 22 | — | -1679.5% | ||
| Q3 22 | — | -1763.8% | ||
| Q2 22 | — | -19229.5% | ||
| Q1 22 | — | -15221.0% |
| Q3 24 | — | — | ||
| Q4 22 | — | -2126.1% | ||
| Q3 22 | — | -2097.9% | ||
| Q2 22 | — | -19574.4% | ||
| Q1 22 | — | -11526.1% |
| Q3 24 | — | — | ||
| Q4 22 | — | $-1.72 | ||
| Q3 22 | — | $-0.01 | ||
| Q2 22 | — | $-0.02 | ||
| Q1 22 | — | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $33.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.0M | $42.5M |
| Total Assets | $13.1M | $45.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | $2.5M | — | ||
| Q4 22 | — | $33.1M | ||
| Q3 22 | — | $42.4M | ||
| Q2 22 | — | $47.9M | ||
| Q1 22 | — | $50.3M |
| Q3 24 | $6.0M | — | ||
| Q4 22 | — | $42.5M | ||
| Q3 22 | — | $46.8M | ||
| Q2 22 | — | $51.3M | ||
| Q1 22 | — | $50.0M |
| Q3 24 | $13.1M | — | ||
| Q4 22 | — | $45.2M | ||
| Q3 22 | — | $49.6M | ||
| Q2 22 | — | $53.0M | ||
| Q1 22 | — | $51.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-4.4M |
| Free Cash FlowOCF − Capex | $-1.6M | $-4.5M |
| FCF MarginFCF / Revenue | -392.9% | -1874.2% |
| Capex IntensityCapex / Revenue | 4.4% | 38.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-14.7M |
8-quarter trend — quarters aligned by calendar period.
| Q3 24 | $-1.6M | — | ||
| Q4 22 | — | $-4.4M | ||
| Q3 22 | — | $-5.2M | ||
| Q2 22 | — | $-2.4M | ||
| Q1 22 | — | $-2.5M |
| Q3 24 | $-1.6M | — | ||
| Q4 22 | — | $-4.5M | ||
| Q3 22 | — | $-5.2M | ||
| Q2 22 | — | $-2.4M | ||
| Q1 22 | — | $-2.5M |
| Q3 24 | -392.9% | — | ||
| Q4 22 | — | -1874.2% | ||
| Q3 22 | — | -2398.9% | ||
| Q2 22 | — | -17553.7% | ||
| Q1 22 | — | -18519.8% |
| Q3 24 | 4.4% | — | ||
| Q4 22 | — | 38.5% | ||
| Q3 22 | — | 2.5% | ||
| Q2 22 | — | 51.1% | ||
| Q1 22 | — | 14.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
